Cross-source evidence timeline

Icatibant research timeline

Follow 64 selected, directly cited source records from December 21, 2007 through November 8, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

64Selected records
15Source years
3Evidence lanes
November 8, 2026Latest source date

Source year

2026

12 records
  1. Literature metadata

    Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.↗

    PubMed lists PMID 24749847 in Clinical and experimental immunology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, and 1 more PubMed publication type, with publication-date metadata of 2014-08 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT05834777↗

    PeptideScanner retained ClinicalTrials.gov record NCT05834777 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was icatibant.↗

  3. Literature metadata

    On-demand treatment of icatibant in a patient of hereditary angioedema with KNG1 mutation.↗

    PubMed lists PMID 42656409 in Genes & diseases as Editorial, with publication-date metadata of 2026-05-14 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT04113109↗

    PeptideScanner retained ClinicalTrials.gov record NCT04113109 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was icatibant.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT05509569↗

    PeptideScanner retained ClinicalTrials.gov record NCT05509569 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was icatibant.↗

  6. Literature metadata

    First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib.↗

    PubMed lists PMID 42219034 in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases as Journal Article, Case Reports, with publication-date metadata of 2026-05-30 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Icatibant for acute hereditary angioedema attacks in pediatric patients: A systematized review.↗

    PubMed lists PMID 42343494 in Allergy and asthma proceedings as Journal Article, Systematic Review, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Icatibant Acts as a Balanced Ligand of MRGPRX2 in Human Skin Mast Cells.↗

    PubMed lists PMID 41008531 in Biomolecules as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-25 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT04488081↗

    PeptideScanner retained ClinicalTrials.gov record NCT04488081 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-03-16, and PeptideScanner's reviewed identity mapping was icatibant.↗

  10. Literature metadata

    In vivo near-infrared fluorescence and SPECT-CT imaging of colorectal Cancer using the bradykinin B2R-specific ligand icatibant.↗

    PubMed lists PMID 36641883 in Journal of photochemistry and photobiology. B, Biology as Journal Article, with publication-date metadata of 2023-01-10 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Icatibant in viral infections.↗

    PubMed lists PMID 37067851 in Infectious diseases (London, England) as Letter, Comment, with publication-date metadata of 2023-04-17 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Assessing the performance of new chromatographic technologies for the separation of peptide epimeric impurities: the case of Icatibant.↗

    PubMed lists PMID 38142950 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Journal Article, with publication-date metadata of 2023-12-22 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2025

5 records
  1. Literature metadata

    Icatibant Use During Pregnancy: A South African Case Series.↗

    PubMed lists PMID 41133754 in Journal of investigational allergology & clinical immunology as Journal Article, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Icatibant for hereditary angioedema.↗

    PubMed lists PMID 20135020 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2009-12 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Exceptional treatment of COVID-19 pneumonia with icatibant.↗

    PubMed lists PMID 35275476 in Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias as Journal Article, with publication-date metadata of 2022-04 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant.↗

    PubMed lists PMID 40559541 in Pathogens (Basel, Switzerland) as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2025-05-27 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT04057131↗

    PeptideScanner retained ClinicalTrials.gov record NCT04057131 at 2026-11-15T22:04:12.435Z. Its registry update date was 2025-02-21, and PeptideScanner's reviewed identity mapping was icatibant.↗

Source year

2024

2 records
  1. Regulatory

    Drugs@FDA application ANDA213773↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 213773 with status AP dated 2024-06-14, and names icatibant acetate among the application record's active ingredients.↗

  2. Literature metadata

    Review of icatibant use in the Winnipeg Regional Health Authority.↗

    PubMed lists PMID 33292436 in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology as Journal Article, with publication-date metadata of 2020-11-11 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2023

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT05407597↗

    PeptideScanner retained ClinicalTrials.gov record NCT05407597 at 2026-11-15T22:04:12.435Z. Its registry update date was 2023-09-07, and PeptideScanner's reviewed identity mapping was icatibant.↗

  2. Regulatory

    Drugs@FDA application ANDA213521↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 213521 with status AP dated 2023-08-14, and names icatibant acetate among the application record's active ingredients.↗

  3. Regulatory

    Federal Register notice 2023-04175↗

    The Federal Register published notice 2023-04175, attributed to FDA and its parent HHS department, on 2023-03-01. Its official title is “Mylan Pharmaceuticals Inc., et.al.; Withdrawal of Approval of 11 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant.↗

Source year

2022

5 records
  1. Literature metadata

    Icatibant in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Case Report.↗

    PubMed lists PMID 33275101 in Journal of investigational allergology & clinical immunology as Case Reports, Journal Article, with publication-date metadata of 2020-12-04 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT04978051↗

    PeptideScanner retained ClinicalTrials.gov record NCT04978051 at 2026-11-15T22:04:12.435Z. Its registry update date was 2022-08-03, and PeptideScanner's reviewed identity mapping was icatibant.↗

  3. Literature metadata

    How satisfactory is on-demand icatibant from the patients' perspective in real life?↗

    PubMed lists PMID 35317892 in Allergy and asthma proceedings as Journal Article, with publication-date metadata of 2022-03-01 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Icatibant , the bradykinin B2 receptor antagonist with target to the interconnected kinin systems.↗

    PubMed lists PMID 22970904 in Expert opinion on pharmacotherapy as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2012-09-13 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT04654351↗

    PeptideScanner retained ClinicalTrials.gov record NCT04654351 at 2026-11-15T22:04:12.435Z. Its registry update date was 2022-03-29, and PeptideScanner's reviewed identity mapping was icatibant.↗

Source year

2021

13 records
  1. Literature metadata

    Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema.↗

    PubMed lists PMID 33851451 in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-05-11 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.↗

    PubMed lists PMID 32919903 in Allergology international : official journal of the Japanese Society of Allergology as Journal Article, Review, with publication-date metadata of 2020-09-09 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00912093↗

    PeptideScanner retained ClinicalTrials.gov record NCT00912093 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was icatibant.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT00997204↗

    PeptideScanner retained ClinicalTrials.gov record NCT00997204 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was icatibant.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT00097695↗

    PeptideScanner retained ClinicalTrials.gov record NCT00097695 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was icatibant.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT00500656↗

    PeptideScanner retained ClinicalTrials.gov record NCT00500656 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was icatibant.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT01386658↗

    PeptideScanner retained ClinicalTrials.gov record NCT01386658 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-08, and PeptideScanner's reviewed identity mapping was icatibant.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT01919801↗

    PeptideScanner retained ClinicalTrials.gov record NCT01919801 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-08, and PeptideScanner's reviewed identity mapping was icatibant.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT02045264↗

    PeptideScanner retained ClinicalTrials.gov record NCT02045264 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-03, and PeptideScanner's reviewed identity mapping was icatibant.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT03888755↗

    PeptideScanner retained ClinicalTrials.gov record NCT03888755 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-03, and PeptideScanner's reviewed identity mapping was icatibant.↗

  11. Literature metadata

    Real-world off-label use of icatibant for acute management of non-hereditary angioedema.↗

    PubMed lists PMID 33738947 in Internal medicine journal as Journal Article, with publication-date metadata of 2021-03 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Regulatory

    Drugs@FDA application ANDA213222↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 213222 with status AP dated 2021-05-21, and names icatibant acetate among the application record's active ingredients.↗

  13. Literature metadata

    Angioedema by MDMA mediated by bradykinin. Role of icatibant acetate.↗

    PubMed lists PMID 32107042 in Medicina clinica as Letter, with publication-date metadata of 2020-02-24 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2020

7 records
  1. Regulatory

    Drugs@FDA application ANDA212081↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 212081 with status AP dated 2020-12-16, and names icatibant acetate among the application record's active ingredients.↗

  2. Regulatory

    Drugs@FDA application ANDA213054↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 213054 with status AP dated 2020-10-05, and names icatibant acetate among the application record's active ingredients.↗

  3. Regulatory

    Drugs@FDA application ANDA211501↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 211501 with status AP dated 2020-09-02, and names icatibant acetate among the application record's active ingredients.↗

  4. Regulatory

    Drugs@FDA application ANDA212446↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 212446 with status AP dated 2020-07-13, and names icatibant acetate among the application record's active ingredients.↗

  5. Regulatory

    Drugs@FDA application ANDA208317↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 208317 with status AP dated 2020-06-18, and names icatibant acetate among the application record's active ingredients.↗

  6. Regulatory

    Drugs@FDA application ANDA211021↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 211021 with status AP dated 2020-03-09, and names icatibant acetate among the application record's active ingredients.↗

  7. Literature metadata

    Angiogenic Host Defense Peptide AG-30/5C and Bradykinin B2 Receptor Antagonist Icatibant Are G Protein Biased Agonists for MRGPRX2 in Mast Cells.↗

    PubMed lists PMID 30651343 in Journal of immunology (Baltimore, Md. : 1950) as Journal Article, Research Support, N.I.H., Extramural, with publication-date metadata of 2019-01-16 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2019

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT03177798↗

    PeptideScanner retained ClinicalTrials.gov record NCT03177798 at 2026-11-15T22:04:12.435Z. Its registry update date was 2019-10-29, and PeptideScanner's reviewed identity mapping was icatibant.↗

  2. Literature metadata

    The identification and chromatographic separation of a new highly analogous impurity of the active pharmaceutical ingredient icatibant.↗

    PubMed lists PMID 30849486 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Journal Article, with publication-date metadata of 2019-03-06 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Regulatory

    Drugs@FDA application ANDA210118↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 210118 with status AP dated 2019-07-15, and names icatibant acetate among the application record's active ingredients.↗

Source year

2018

2 records
  1. Literature metadata

    Icatibant: HOE 140, JE 049, JE049.↗

    PubMed lists PMID 15563238 in Drugs in R&D as Journal Article, Review, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Icatibant: HOE 140, JE 049, JE049.↗

    PubMed lists PMID 15991885 in Drugs in R&D as Journal Article, Review, with publication-date metadata of 2005 (year precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2017

2 records
  1. Literature metadata

    Icatibant for the treatment of hereditary angioedema.↗

    PubMed lists PMID 23249729 in The Annals of pharmacotherapy as Comparative Study, Journal Article, Review, with publication-date metadata of 2012-12-18 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Icatibant as acute treatment for hereditary angioedema in adults.↗

    PubMed lists PMID 27123689 in Expert review of clinical pharmacology as Journal Article, Review, with publication-date metadata of 2016-05-13 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2016

2 records
  1. Literature metadata

    [Prophylactic use of icatibant before tracheal intubation of a patient with hereditary angioedema type III. (A literature review of perioperative management of patients with hereditary angioedema typ…↗

    PubMed lists PMID 24931134 in Revista espanola de anestesiologia y reanimacion as Case Reports, Journal Article, Review, with publication-date metadata of 2014-06-13 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01457430↗

    PeptideScanner retained ClinicalTrials.gov record NCT01457430 at 2026-11-15T22:04:12.435Z. Its registry update date was 2016-10-18, and PeptideScanner's reviewed identity mapping was icatibant.↗

Source year

2014

2 records
  1. Literature metadata

    Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).↗

    PubMed lists PMID 17418383 in The Journal of allergy and clinical immunology as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2007-04-05 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Regulatory

    Federal Register notice 2014-07331↗

    The Federal Register published notice 2014-07331, attributed to FDA and its parent HHS department, on 2014-04-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; FIRAZYR,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant.↗

Source year

2013

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00223704↗

    PeptideScanner retained ClinicalTrials.gov record NCT00223704 at 2026-11-15T22:04:12.435Z. Its registry update date was 2013-11-25, and PeptideScanner's reviewed identity mapping was icatibant.↗

  2. Literature metadata

    Icatibant in hereditary angioedema: news and challenges.↗

    PubMed lists PMID 21595592 in Expert review of clinical immunology as Journal Article, Review, with publication-date metadata of 2011-05 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. Management of adult patients with icatibant in hereditary angioedema.↗

    PubMed lists PMID 21788245 in Emergency medicine journal : EMJ as Journal Article, Review, with publication-date metadata of 2011-08 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2011

2 records
  1. Regulatory

    Drugs@FDA application NDA022150↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 022150 with status AP dated 2011-08-25, and names icatibant acetate among the application record's active ingredients.↗

  2. Regulatory

    Federal Register notice 2011-12543↗

    The Federal Register published notice 2011-12543, attributed to FDA and its parent HHS department, on 2011-05-23. Its official title is “Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant.↗

Source year

2007

1 record
  1. Regulatory

    Federal Register notice E7-24812↗

    The Federal Register published notice E7-24812, attributed to FDA and its parent HHS department, on 2007-12-21. Its official title is “Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant.↗